ALK and chronic myelogenous leukemia, BCR-ABL1 positive: For example, imatinib, which targets breakpoint cluster region-abelson (BCR-ABL), is used to treat patients with chronic myelogenous leukemia [4] and crizotinib, which targets anaplastic lymphoma kinase (ALK), is used to treat patients with ALK-positive non-small cell lung cancer [5].